Tissue Control | List of Frontiers open access articles

Mini Review

Published on 07 Aug 2020

Mammary Adipose Tissue Control of Breast Cancer Progression: Impact of Obesity and Diabetes

in Molecular and Cellular Oncology

Vittoria D’Esposito
Maria Rosaria Ambrosio
Mario Giuliano
Serena Cabaro
Claudia Miele
Francesco Beguinot
Pietro Formisano

Frontiers in Oncology

doi 10.3389/fonc.2020.01554

12,843 views
59 citations

Perspective

Published on 03 Mar 2017

DGK-α: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy

in Signaling

Elfriede Noessner

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2017.00016

16,110 views
37 citations

Review

Published on 13 Sep 2019

6-Sulfo LacNAc (Slan) as a Marker for Non-classical Monocytes

in Antigen Presenting Cell Biology

Thomas P. Hofer
Arjan A. van de Loosdrecht
Christiane Stahl-Hennig
Marco A. Cassatella
Loems Ziegler-Heitbrock

Frontiers in Immunology

doi 10.3389/fimmu.2019.02052

14,884 views
42 citations

Original Research

Published on 29 Nov 2021

Double Strike Approach for Tumor Attack: Engineering T Cells Using a CD40L:CD28 Chimeric Co-Stimulatory Switch Protein for Enhanced Tumor Targeting in Adoptive Cell Therapy

in T Cell Biology

Luis Felipe Olguín-Contreras
Anna N. Mendler
Grzegorz Popowicz
Bin Hu
Elfriede Noessner

Frontiers in Immunology

doi 10.3389/fimmu.2021.750478

9,086 views
14 citations

Original Research

Published on 12 Apr 2019

Dosiomics: Extracting 3D Spatial Features From Dose Distribution to Predict Incidence of Radiation Pneumonitis

in Radiation Oncology

Bin Liang
Hui Yan
Yuan Tian
Xinyuan Chen
Lingling Yan
Tao Zhang
Zongmei Zhou
Lvhua Wang
Jianrong Dai

Frontiers in Oncology

doi 10.3389/fonc.2019.00269

14,195 views
163 citations

Original Research

Published on 17 Nov 2021

Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells

in Cancer Immunity and Immunotherapy

Camilla M. Grunewald
Corinna Haist
Carolin König
Patrick Petzsch
Arthur Bister
Elfriede Nößner
Constanze Wiek
Kathrin Scheckenbach
Karl Köhrer
Günter Niegisch

Frontiers in Immunology

doi 10.3389/fimmu.2021.782448

8,572 views
31 citations

Original Research

Published on 02 Jun 2021

Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens

in Cancer Immunity and Immunotherapy

Gitte Holmen Olofsson
Manja Idorn
Ana Micaela Carnaz Simões
Pia Aehnlich
Signe Koggersbøl Skadborg
Elfriede Noessner
Reno Debets
Bernhard Moser
Özcan Met
Per thor Straten

Frontiers in Immunology

doi 10.3389/fimmu.2021.645131

12,430 views
43 citations

Articles

Mammary Adipose Tissue Control of Breast Cancer Progression: Impact of Obesity and Diabetes

DGK-α: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy

6-Sulfo LacNAc (Slan) as a Marker for Non-classical Monocytes

Double Strike Approach for Tumor Attack: Engineering T Cells Using a CD40L:CD28 Chimeric Co-Stimulatory Switch Protein for Enhanced Tumor Targeting in Adoptive Cell Therapy

Dosiomics: Extracting 3D Spatial Features From Dose Distribution to Predict Incidence of Radiation Pneumonitis

Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells

Vγ9Vδ2 T Cells Concurrently Kill Cancer Cells and Cross-Present Tumor Antigens